BPIFB4 and cancer: Once again, no significant changes of monocyte phenotype were reported following LAV-BPIFB4 treatment (Supplementary Materials Figure S3D,E), suggesting its peculiar senotherapeutic activity on T-cell immunesenescence in cancer patients.